EQL PHARMA AB Cash Flow Quality Index
EQL PHARMA AB cash flow quality index. EQL PHARMA AB (7JK) has a Cash Flow Quality Index of 1.37x as of December 2025. Operating cash flow of €13.44 Million exceeds net income of €9.79 Million, indicating high earnings quality where cash backs reported profits. Explore EQL PHARMA AB (7JK) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of EQL PHARMA AB (2022–2026)
Cash flow quality index of EQL PHARMA AB from 2022 to 2026. Historical Cash Flow Quality Index for EQL PHARMA AB across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. See debt-free asset ratio of EQL PHARMA AB to measure how much of total assets are equity-financed.
EQL PHARMA AB Cash Flow Quality Index by Year (2022–2026)
EQL PHARMA AB cash flow quality index by year from 2022 to 2026. Year-by-year earnings quality comparison for EQL PHARMA AB. For the full cash flow conversion analysis, see 7JK cash generation efficiency.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2026 | 2.26x | €28.36 Million | €12.54 Million | ▲ +495.7% |
| 2025 | -0.57x | €-24.65 Million | €43.12 Million | ▼ -13.5% |
| 2024 | -0.50x | €-11.44 Million | €22.70 Million | ▼ -156.4% |
| 2023 | 0.89x | €27.62 Million | €30.92 Million | ▼ -32.6% |
| 2022 | 1.33x | €41.83 Million | €31.55 Million | — |